Effectiveness and duration of protection of a fourth dose of Coronavirus disease 2019 messenger RNA vaccine among long-term care residents in Ontario, Canada

We estimated the effectiveness of a fourth dose of mRNA COVID-19 vaccine against Omicron infections and severe outcomes over time among long-term care residents in Ontario, Canada. Fourth doses provide additional protection against Omicron-related outcomes, but the protection wanes over time, with more waning seen against infection than severe outcomes.

View Source

Information

Citation

Grewal R, Nguyen L, Buchan SA, Wilson SE, Costa AP, Kwong JC. J Infect Dis. 2023; 227(8):977–80. Epub 2022 Dec 3.

View Source

Contributing ICES Scientists

Research Programs

Populations & Public Health

Associated Topics

Associated Sites

ICES Central

Discover More

Journal Article

27/11/2023

Low-dose methotrexate and serious adverse events among older adults with chronic kidney disease

Muanda FT, Blake PG, Weir MA, Ahmadi F, McArthur E, Sontrop JM, Urquhart BL, Kim RB, Garg AX. JAMA Netw Open. 2023; 6(11):e2345132. Epub 2023 Nov 27.

Journal Article

24/11/2023

Protection conferred by COVID-19 vaccination, prior SARS-CoV-2 infection, or hybrid immunity against Omicron-associated severe outcomes among community-dwelling adults

Lee N, Nguyen L, Austin PC, Brown KA, Grewal R, Buchan SA, Nasreen S, Gubbay J, Schwartz KL, Tadrous M, Wilson K, Wilson SE, Kwong JC. Clin Infect Dis. 2024; Nov 24 {Epub ahead of print].

Journal Article

21/11/2023

SARS-CoV-2 vaccination prevalence by mental health diagnosis: a population-based cross-sectional study in Ontario, Canada

Kurdyak P, Lebenbaum M, Patrikar A, Rivera L, Lu H, Scales DC, Guttmann A. CMAJ Open. 2023; 11(6):E1066-74. Epub 2023 Nov 21.

See All